Halothane inhalation inhibits the metabolism of chlorzoxazone, a substrate for CYP2E1, in rabbits

被引:4
|
作者
Tateishi, T [1 ]
Watanabe, M [1 ]
Nakura, H [1 ]
Tanaka, M [1 ]
Kumari, T [1 ]
Aoki, T [1 ]
Kobayashi, S [1 ]
机构
[1] ST MARIANNA UNIV, SCH MED, DEPT ANESTHESIOL, KAWASAKI, KANAGAWA 216, JAPAN
来源
ANESTHESIA AND ANALGESIA | 1997年 / 85卷 / 01期
关键词
D O I
10.1097/00000539-199707000-00035
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
We demonstrated the inhibitory effect of halothane (HAL) inhalation on the metabolism of chlorzoxazone (CZZ), a substrate for CYP2E1, in a bolus and a continuous injection study in rabbits receiving artificial ventilation. In a bolus injection study, the inhalation of 1.0% HAL significantly increased the half-life and the area under the curve and decreased the clearance of CZZ compared with those variables in midazolam administration. In a continuous injection study, the eff eet of various concentrations of inhaled HAL on plasma CZZ concentration at steady state was compared. Systolic and diastolic arterial blood pressure were decreased dose-dependently after 0.5%, 1.0%, or 2.0% HAL was inhaled. Although the plasma concentration of CZZ was increased 2.5-fold after 3 h of HAL inhalation, there was no significant difference in mean plasma concentrations among the groups treated with 0.5%, 1.0%, or 2.0% HAL. In contrast, the plasma concentration of lidocaine, a substrate for CYP3A, remained unchanged after 1.0% HAL was inhaled. These results suggest that general anesthesia obtained with HAL inhalation will affect the metabolism of drugs administered concomitantly when the drug is a substrate for CYP2E1.
引用
收藏
页码:199 / 203
页数:5
相关论文
共 50 条
  • [31] Computational docking simulations of oxidative metabolism of CYP2E1
    Cooper, Kasa B.
    Miller, Grover P.
    Perry, Martin D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [32] Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures
    Hartman, Jessica H.
    Letzig, Lynda G.
    Roberts, Dean W.
    James, Laura P.
    Fifer, E. Kim
    Miller, Grover P.
    BIOCHEMICAL PHARMACOLOGY, 2015, 97 (03) : 341 - 349
  • [33] The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain
    Garcia-Suastegui, W. A.
    Ramos-Chavez, L. A.
    Rubio-Osornio, M.
    Calvillo-Velasco, M.
    Atzin-Mendez, J. A.
    Guevara, J.
    Silva-Adaya, D.
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2017, 2017
  • [34] ACETAMINOPHEN METABOLISM IN PATIENTS WITH DIFFERENT CYP2E1 GENOTYPES
    TSUTSUMI, M
    UESHIMA, Y
    TAKASE, S
    MATSUDA, Y
    KAWAHARA, H
    HEPATOLOGY, 1995, 22 (04) : 1585 - 1585
  • [35] Mutagenesis and computational docking simulations of CYP2E1 metabolism
    Levy, Joseph W.
    Miller, Grover P.
    Perry, Martin D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [36] ACETAMINOPHEN METABOLISM IN SUBJECTS WITH DIFFERENT CYP2E1 GENOTYPES
    TSUTSUMI, M
    WANG, JS
    UESHIMA, Y
    TAKASE, S
    TAKADA, A
    HEPATOLOGY, 1994, 20 (04) : A409 - A409
  • [37] CYP2E1 in 1,4-dioxane metabolism and liver toxicity: insights from CYP2E1 knockout mice study
    Wang, Yewei
    Charkoftaki, Georgia
    Orlicky, David J.
    Davidson, Emily
    Aalizadeh, Reza
    Sun, Ning
    Ginsberg, Gary
    Thompson, David C.
    Vasiliou, Vasilis
    Chen, Ying
    ARCHIVES OF TOXICOLOGY, 2024, 98 (10) : 3241 - 3257
  • [38] In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African green monkeys: Induction by chronic nicotine treatment
    Lee, Anna M.
    Yue, Jiang
    Tyndale, Rachel F.
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (09) : 1508 - 1515
  • [39] The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone
    Loizou, GD
    Cocker, J
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2001, 20 (07) : 321 - 327
  • [40] Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation
    Burckart, GJ
    Frye, RF
    Kelly, P
    Branch, RA
    Jain, A
    Fung, JJ
    Starzl, TE
    Venkataramanan, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (03) : 296 - 302